Case report reveals effective management of refractory thrombotic thrombocytopenic purpura using caplacizumab and rituximab.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: